• Rethinking Long COVID: Targeting Root Causes First

    Mar 05 | Diagnostics World News | At February’s Integrative Healthcare Symposium, Dr. George Schatz urged clinicians to rethink how they evaluate long COVID. For patients who still struggle with long-term fatigue, brain fog, palpitations, and sleep disruption, he proposed a diagnostics-first framework that prioritizes mechanism over labels. More

  • Blood Test Suggests if Gallstones Could Progress to Cancer

    Mar 04 | Diagnostics World News | The vast number and diversity of chemicals that exist in the natural world represent both the cause of and solution to all the world’s problems. As such, they are foundational, high-stakes agents irrespective of the biological system—be they comprised of plants, microorganisms, or human beings. More

  • Epigenetic Instability Metric Could Aid Early Cancer Detection Efforts

    Mar 03 | Diagnostics World News | The quest to marry different DNA methylation technologies for the purpose of early cancer detection has been ongoing for several decades now. Among the recent breakthroughs is an “epigenetic instability index” (EII) measuring the randomness of methylation rather than just consistent, fixed changes. More

  • Sanofi’s New CEO, PacBio, iHope Collaboration, Astoriom Further Expands in North America

    Feb 26 | Diagnostics World News | Sanofi appoints Belén Garijo as chief executive officer; PacBio collaborates with iHope; Astoriom acquires Precision Stability Storage, expanding its sample management capabilities in the U.S.; and more. More

  • Follow the Money: Personalized Therapy for Colorectal Cancer, Methyl-Copying PCR Platform, More

    Feb 25 | Diagnostics World News | Neogap Therapeutics advances their ongoing clinical study for personalized therapy for advanced colorectal cancer; Syndex Bio introduced its proprietary mcPCR (methyl-copying PCR) platform; and more. More

  • Precision Medicine Needs Precision Engineered Diagnostic Systems

    Feb 20 | Diagnostics World News | Precision medicine is often described as the future of healthcare. But from an engineering standpoint, it’s already here, and it’s forcing diagnostic instruments to evolve faster than most development cycles are comfortable with. We’re asking instruments to do more than confirm a suspected diagnosis. We’re asking them to deliver specificity, speed, and confidence in environments that aren’t always predictable. That’s a major shift from the days when “good enough” screening could drive clinical decisions. More

  • Clock Model Predicts When Alzheimer’s Symptoms Will Appear

    Feb 19 | Diagnostics World News | Researchers from the Foundation for the National Institutes of Health (FNIH), Washington University in St. Louis, the University of California San Francisco, the University of Wisconsin-Madison, and more have published results of a study using a single plasma biomarker sample to estimate not only the probability of an Alzheimer’s Disease diagnosis, but when symptoms will develop. More

  • PacBio’s Rare Disease, ASO Push

    Feb 17 | Diagnostics World News | PacBio has announced several rare disease genomics programs so far this year. The most recent partner organizations include iHope, N-Lorem, EspeRare, UW Medicine, and Seattle Children’s Hospital. More

  • Zentropy: A New Framework to Transform Medical Prediction

    Feb 13 | Diagnostics World News | A research team at Penn State is reshaping the future of diagnostics by embedding the laws of thermodynamics directly into artificial intelligence (AI). Their framework, called zentropy-embedded neural networks (ZENN) promises to improve how clinicians interpret complex, multi-source diagnostic data, from brain scans to blood tests. More

  • UK Consortium Builds Cancer Dataset and AI Models with 10x Xenium Spatial Platform

    Feb 06 | Diagnostics World News | PharosAI, a research consortium of four UK institutions, plans to use the 10x Genomics Xenium spatial platform to build one of the world's most comprehensive multimodal cancer datasets and pair them with advanced AI models and analytical capabilities. They plan to democratize access to these datasets, ensuring they are securely available to a broad community of researchers and innovators. More
View more articles

 
DXX-Industry-spotlight

merck


Custom Diagnostic Antibody Development & Manufacturing Services

Overcome Process Challenges by outsourcing your custom antibody production to us. How partnering with an antibody production expert can improve your assay, accelerate launch, and maintain your manufacturing.

Learn more